New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

The new treatment, which uses a type of immune cell called natural killer cells, promoted complete remission in several ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Neoadjuvant PD-1 blockade in dMMR tumors "could potentially eradicate the need for chemotherapy, radiation, and surgery in ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

We are navigating political interference, institutional instability, and growing uncertainty across the cancer research ...